Elevation Oncology Inc (ELEV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elevation Oncology Inc (ELEV) has a cash flow conversion efficiency ratio of -0.272x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.71 Million) by net assets ($46.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Elevation Oncology Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Elevation Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ELEV liabilities breakdown for a breakdown of total debt and financial obligations.
Elevation Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elevation Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Archtis Ltd
AU:AR9
|
-0.252x |
|
Zuleika Gold Ltd
AU:ZAG
|
-0.049x |
|
Puma Exploration Inc
V:PUMA
|
-0.007x |
|
Bcal Diagnostics Ltd
AU:BDX
|
-0.999x |
|
Gillanders Arbuthnot & Company Limited
NSE:GILLANDERS
|
0.009x |
|
Rubean AG
F:R1B
|
N/A |
|
Adagio Medical Holdings, Inc Common Stock
NASDAQ:ADGM
|
2.293x |
|
Nyesa Valores Corp SA
MC:NYE
|
-0.331x |
Annual Cash Flow Conversion Efficiency for Elevation Oncology Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Elevation Oncology Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Elevation Oncology Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $60.02 Million | $-36.36 Million | -0.606x | +40.90% |
| 2023-12-31 | $54.81 Million | $-56.18 Million | -1.025x | +41.21% |
| 2022-12-31 | $49.03 Million | $-85.48 Million | -1.743x | -713.12% |
| 2021-12-31 | $140.70 Million | $-30.17 Million | -0.214x | -140.24% |
| 2020-12-31 | $-23.08 Million | $-12.30 Million | 0.533x | -42.58% |
| 2019-12-31 | $-5.87 Million | $-5.45 Million | 0.928x | -- |
About Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more